ACT 16116/2024

—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL

Verfahrensdetails: Status
—
Verfahrensart
Verletzung
Kategorie
Hauptverletzungsklage
Parteien: Kläger
Sanofi SA (and related Sanofi entities)
Vertreter: Frédéric Chevallier (McDermott Will & Schulte)
Beklagte
Accord Healthcare entities
STADAPHARM GmbH
STADA Arzneimittel AG
Reddy Pharma SAS
betapharm Arzneimittel GmbH
Zentiva France
Zentiva Pharma GmbH
Zentiva, k.s.
Vertreter: Jules Fabre (Taylor Wessing); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing)
Division: Munich LD
Richter: Matthias Zigann · Presiding Judge / Judge-Rapporteur
Technology: Pharmaceuticals · Oncology · Pharmaceutical & Medical
Sprache: —
Erste Entscheidung: 15. Sept. 2025

Entscheidungen

2025-09-15
Infringement Action
Procedural scheduling order by Munich Local Division (UPC_CFI_145-148/2024, 15 September 2025) summoning party experts to oral hearing on 14-17 October 2025 in four consolidated infringement proceedings by Sanofi entities against Accord Healthcare, STADA, Reddy Pharma/betapharm and Zentiva groups concerning EP 2 493 466.
Rechtsfragen:Summons of party experts to oral hearing (R. 177.2, 181.1 RoP)Consolidated infringement actions

Dokumente